This study is in progress, not accepting new patients
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Loxo Oncology, Inc.
- Links
- A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
- ID
- NCT04211337
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 400 study participants
- Last Updated